Preferences help
enabled [disable] Abstract
Number of results
2013 | 3 | 1 | 59-62
Article title

Nowe możliwości leczenia uogólnionego raka piersi

Title variants
New possibilities of therapy for advanced, metastatic breast cancer
Languages of publication
Despite improving screening methods, diagnosis of early breast cancers, new therapies the prognosis in breast cancer remains poor. Advanced, metastatic breast cancer is an incurable, persistent disease. Hormonotherapy is the main treatment of receptor positive breast cancer patients. Till now in case of hormone resistant disease chemotherapy was the only choice nowadays there is possibility to use combination of endocrine and targeted therapy, the mTOR inhibitor everolimus. In HER2 receptor positive breast cancer therapy with trasuzumab improved treatment results. Despite many new treatment methods there is still need for new therapies which could improve the patients outcome.
Mimo udoskonalania metod badań przesiewowych, wczesnego wykrywania raka piersi i nowych terapii rokowanie w raku piersi pozostaje złe. Zaawansowany, uogólniony rak piersi jest chorobą przewlekłą, nieuleczalną. Podstawową metodą leczenia systemowego nowotworów dodatnich receptorowo jest hormonoterapia. Do niedawna w przypadku oporności metodą z wyboru pozostawała chemioterapia, obecnie możliwe jest zastosowanie skojarzenia leczenia hormonalnego z leczeniem celowanym ewerolimusem – inhibitorem mTOR. W rakach z nadekspresją receptora HER2 rokowanie pacjentek zmieniło wprowadzenie do leczenia trastuzumabu. Mimo dostępności wielu metod leczenia nadal poszukuje się nowych, które poprawią wyniki leczenia.

Physical description
  • Klinika Onkologii, Centrum Medyczne Kształcenia Podyplomowego, Europejskie Centrum Zdrowia Otwock
  • Largillier R., Ferrero J.M., Doyen J. et al.: Prognostic factors in 1038 women with metastatic breast cancer. Ann. Oncol. 2008; 19: 2012-9.
  • Andre F., Slimane K., Bachelot T. et al.: Breast cancer with Synchronous metastases: trends in survival during a 14-Year Period. J. Clin. Oncol. 2004; 22: 3302-8.
  • Sundquist M., Eriksson Z., Tejler G. et al.: Trends in survival in metastatic breast cancer. Eur. J. Cancer 2010; 8(3): 191 (abstract 453).
  • Goldhirsch A., Wood W.C., Coates A.S. et al.: Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann. Oncol. 2011; 22 (8): 1736-47.
  • Harris L., Fritsche H., Mennel R. et al.: American Society of clinical oncology 2007 update of recommendations for the use the tumor markers in breast cancer. J. Clin. Oncol. 2007; 25(33): 5287-312.
  • Slamon D.J., Clark G.M., Wong S.G.: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-82.
  • Dawood S., Broglio K., Buzdar A.U.: Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutionalbased review. J. Clin. Oncol. 2010; 28: 92-8.
  • Verma S., Miles D., Gianni L. et al.: Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer. N. Engl. J. Med. 2012; 5: 1-9.
  • Baselga J., Gelman K.A., Verma S. et al.: Phase II of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J. Clin. Oncol. 2012; 28(7): 1138-44.
  • Baselga J., Cortés J., Kim S. et al.: Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer. N. Engl. J. Med. 2011; 8: 1-11.
  • Verma S., Miles D., Gianni L. et al.: Trastuzumab Emtasine for HER2-Positive Advanced Breast Cancer. N. Engl. J. Med. 2012; 367: 1783-91.
Document Type
Publication order reference
YADDA identifier
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.